MDGL Description — Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
Free MDGL Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.53 out of 4) 60th percentile
(ranked higher than approx. 60% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|